CN116421665A - Pharmaceutical composition for treating rhinitis - Google Patents
Pharmaceutical composition for treating rhinitis Download PDFInfo
- Publication number
- CN116421665A CN116421665A CN202310206553.1A CN202310206553A CN116421665A CN 116421665 A CN116421665 A CN 116421665A CN 202310206553 A CN202310206553 A CN 202310206553A CN 116421665 A CN116421665 A CN 116421665A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhinitis
- pharmaceutical composition
- herba
- treating rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 8
- 239000006002 Pepper Substances 0.000 claims abstract description 8
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 8
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims description 9
- 239000002674 ointment Substances 0.000 claims description 6
- 239000009670 cang er zi wan Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 241000722363 Piper Species 0.000 claims 3
- 230000000694 effects Effects 0.000 abstract description 10
- 244000302909 Piper aduncum Species 0.000 abstract description 7
- 241001166194 Geranium wilfordii Species 0.000 abstract description 6
- 230000005764 inhibitory process Effects 0.000 abstract description 6
- 244000052769 pathogen Species 0.000 abstract description 6
- 208000024891 symptom Diseases 0.000 abstract description 5
- 241000191967 Staphylococcus aureus Species 0.000 abstract description 2
- 241000194017 Streptococcus Species 0.000 abstract description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 abstract description 2
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 abstract description 2
- 229960001573 cabazitaxel Drugs 0.000 abstract description 2
- 208000037797 influenza A Diseases 0.000 abstract description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 abstract description 2
- 241000208152 Geranium Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 4
- 210000001944 turbinate Anatomy 0.000 description 4
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 206010039101 Rhinorrhoea Diseases 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 241000758794 Asarum Species 0.000 description 1
- 241001655736 Catalpa bignonioides Species 0.000 description 1
- 241000928504 Centipeda minima Species 0.000 description 1
- 240000001624 Espostoa lanata Species 0.000 description 1
- 235000009161 Espostoa lanata Nutrition 0.000 description 1
- 241001071795 Gentiana Species 0.000 description 1
- 241000208150 Geraniaceae Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Animal Husbandry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating rhinitis, which is prepared from the following raw materials in parts by weight: 100-150 parts of herba nigellae and 5-20 parts of pepper. The geranium wilfordii has strong resistance to pathogens, has inhibition effect to various pathogens, has a certain inhibition effect to pathogens such as staphylococcus aureus, streptococcus b, streptococcus pneumoniae, cabazitaxel and the like, and has a certain inhibition effect to influenza A. In the application, the geranium wilfordii and the wild pepper are used together, so that the rhinitis can be effectively treated, and the rhinitis symptoms can be improved.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a pharmaceutical composition for treating rhinitis.
Background
Rhinitis is acute or chronic inflammation caused by damage of nasal mucosa or submucosal tissue due to virus infection, germ infection, stimulus, etc. Rhinitis causes excessive mucus, which often causes symptoms such as runny nose, nasal obstruction, etc.
At present, various medicines for treating rhinitis, in particular to traditional Chinese medicines, the traditional Chinese medicine has the effect of treating both principal and secondary aspect of disease in treating the disease, is safe and has no toxic or side effect, for example, patent CN 108042692A is rhinitis powder, and comprises the following raw materials: fructus Xanthii, herba asari, borneolum Syntheticum, ramulus Cinnamomi, herba Menthae, glycyrrhrizae radix, pericarpium Citri Tangerinae, bulbus Fritillariae Thunbergii, herba Centipedae, rhizoma Pinelliae and rhizoma Typhonii. In another example, patent CN 101590107A is a rhinitis ointment which comprises 45-55 parts of centipeda minima, 3-9 parts of magnolia flower, 8-15 parts of gentian, 2-5 parts of angelica dahurica, 2-5 parts of asarum, 0.1-0.6 part of glycyrrhizic acid and 0.5-2 parts of baicalin, and has the effects of dispelling wind and dispelling cold, dredging qi, relieving swelling and pain and repairing nasal mucosa pathological tissues. The main traditional Chinese medicine components are fructus Xanthii, herba Centipedae, radix Gentianae and the like, and the composition has more components.
Disclosure of Invention
The invention provides a pharmaceutical composition for treating rhinitis.
In order to achieve the above purpose, the technical scheme of the invention is as follows:
a pharmaceutical composition for treating rhinitis is prepared from the following raw materials in parts by weight: 100-150 parts of herba nigellae and 5-20 parts of pepper.
Preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 100 parts of herba nigellae and 10-20 parts of pepper.
Preferably, the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 100 parts of herba nigellae and 10 parts of pepper.
Preferably, one or more of fructus Xanthii and dried nidus Vespae can be added.
Further, the dosage form of the medicine is one selected from granules, tablets, capsules, ointment and spray.
The beneficial effects of the invention are as follows:
geranium (school name: geranium wilfordii maxim.) is also called Geranium mouth, geranium crotalarium mouth, herba Polygoni Avicularis, herba Cynomorii, and herba Geranii. The source is as follows: the product is dry aerial parts of Geranium geranium of Geraniaceae, geranium or Geranium wilfordii, the former is called as Geranium longifolium, the latter is called as Geranium serrulatum, and the latter two are picked up and bundled into bundles and dried in the sun when fruits are near maturity in summer and autumn.
The geranium wilfordii has strong resistance to pathogens, has inhibition effect to various pathogens, has a certain inhibition effect to pathogens such as staphylococcus aureus, streptococcus b, streptococcus pneumoniae, cabazitaxel and the like, and has a certain inhibition effect to influenza A. In the application, the geranium wilfordii and the wild pepper are used together, so that the rhinitis can be effectively treated, and the rhinitis symptoms can be improved.
Detailed Description
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention. Based on the embodiments of the present invention, other embodiments that a person skilled in the art would obtain without carrying out a breakthrough study are all within the scope of the present invention. In addition, the technical features of the embodiments of the present invention described below may be combined with each other as long as they do not collide with each other.
Example 1
A pharmaceutical composition for treating rhinitis is prepared from the following raw materials in parts by weight: 100 parts of herba nigellae and 10 parts of pepper.
Grinding herba Laozi and fructus Zanthoxyli, and stirring with vaseline to obtain paste.
And (5) coating the coating. Dipping cotton balls into the medicinal paste, and then plugging into nostrils. The medicine is preferably taken before sleeping once a day for two hours each time. 10 days is a treatment course.
The clinical patient has 500 cases of application cases, and the cure rate reaches 85% (the cure performance is that the nasal cavity ventilation is good, the headache is disappeared, the secretion is reduced), the effective rate is 12% (the effective performance is that the nasal cavity ventilation condition and the turbinate condition are improved in advance, but the nasal cavity ventilation condition and the turbinate condition are not completely normal yet).
The rhinitis ointment of the invention has simple composition, pure traditional Chinese medicine components and no toxic or side effect.
Several examples of clinical applications are as follows:
examples 1, some: girls, three years old, follow the people in the city of China, the catalpa county. Five times of rhinitis, the nose does not run out of nasal discharge and does not sneeze after suffering from rhinitis for one year.
Example 2, zheng: men, 36 years old. Following the Yi Zhengan county, the people suffering from the hypertrophy of the nasal turbinates have the rhinitis ointment for eight years, after two treatment courses, the nasal turbinates are not hypertrophic any more, all rhinitis symptoms disappear, and no recurrence occurs for nine years.
Examples 3, sun Mou: men, 12 years old. The Zunyi city is broadcast to the district, the allergic rhinitis is affected for three years, and after one treatment course of the rhinitis cream is used, all rhinitis symptoms completely disappear and are not developed for five years.
Examples 4, wang Mou, women, 54 years old, follow the city sink district. Allergic rhinitis for 20 years. The rhinitis ointment is not developed three years after two treatment courses.
While the invention has been described in connection with what is presently considered to be the most practical and preferred embodiment, it is to be understood by those skilled in the art that the foregoing is merely exemplary of the invention and that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications, equivalents, and alternatives falling within the spirit and principles of the invention.
Claims (5)
1. The pharmaceutical composition for treating rhinitis is characterized by being prepared from the following raw materials in parts by weight: 100-150 parts of herba nigellae and 5-20 parts of pepper.
2. The pharmaceutical composition for treating rhinitis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 100 parts of herba nigellae and 10-20 parts of pepper.
3. The pharmaceutical composition for treating rhinitis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight: 100 parts of herba nigellae and 10 parts of pepper.
4. The pharmaceutical composition for treating rhinitis according to claim 1, further comprising one or more of fructus Xanthii and dried nidus Vespae.
5. The pharmaceutical composition for treating rhinitis according to any one of claims 1 to 4, wherein the dosage form of the drug is selected from one of granules, tablets, capsules, ointments and sprays.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310206553.1A CN116421665A (en) | 2023-03-06 | 2023-03-06 | Pharmaceutical composition for treating rhinitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310206553.1A CN116421665A (en) | 2023-03-06 | 2023-03-06 | Pharmaceutical composition for treating rhinitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116421665A true CN116421665A (en) | 2023-07-14 |
Family
ID=87082251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310206553.1A Pending CN116421665A (en) | 2023-03-06 | 2023-03-06 | Pharmaceutical composition for treating rhinitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116421665A (en) |
-
2023
- 2023-03-06 CN CN202310206553.1A patent/CN116421665A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101468039B (en) | Method for preparing compound double-layer sustained-release medicinal membrane for treating oral mucosal disease | |
| CN101590107B (en) | Rhinitis ointment | |
| CN103110868A (en) | Skin care solution and preparation method thereof | |
| CN102755573A (en) | External use traditional Chinese medicine for treating onychomycosis | |
| CN111514231A (en) | Application of ephedra and apricot lung-ventilating traditional Chinese medicine composition as influenza virus treatment medicine | |
| CN116421665A (en) | Pharmaceutical composition for treating rhinitis | |
| CN110638915A (en) | Traditional Chinese medicine composition for treating chronic rhinitis and preparation method thereof | |
| CN113616721A (en) | Pharmaceutical composition for treating oral ulcer and preparation method and application thereof | |
| CN102727804B (en) | Traditional Chinese medicine composition for treating abscess and boil and preparation method thereof | |
| CN104623443A (en) | Traditional Chinese medicine for treating skin erosion | |
| CN101856488A (en) | Chinese medicament for treating tracheitis | |
| CN102068676A (en) | Medicament for treating chilblain | |
| CN104491462B (en) | A kind of pharmaceutical composition for the treatment of scald | |
| CN104069176B (en) | Stick scattered and preparation method thereof in a kind of oral cavity | |
| CN107669764A (en) | Pharmaceutical composition of combination therapy of Chinese and western bronchitis and preparation method thereof | |
| CN107638468A (en) | It is a kind of to be used to treat Chinese medicine composition of rhinitis chronic and application thereof | |
| CN102579885B (en) | Chinese herbal medicament for treating recurrent oral ulcer | |
| CN100360163C (en) | Externally-applied Chinese medicine for treating acute and chronic pharyngolaryn gitis and its therapeutic belt thereof | |
| CN101040973A (en) | Baiguo oral liquor for treating asthma | |
| CN104474272A (en) | Traditional Chinese medicine composition for treating lower limb ulcer | |
| CN1259952C (en) | External used ointment of Chinese medicine for acute or chronic tympanitis | |
| CN104814914A (en) | Chinese herbal medicine acne removal facial mask and preparation method thereof | |
| CN105031293A (en) | Patch for muscles and bones | |
| CN105168991A (en) | Traditional Chinese medicinal composition for treating chronic bronchitis | |
| CN104971209A (en) | Externally used agent for treating tinea pedis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |